Regnier R
Service de Radiothérapie et de Médecine Nucléaire, Institut Jules Bordet, Bruxelles.
Rev Med Brux. 1992 May;13(5):172-6.
Total body irradiation produces a sufficient immunosuppression to prevent an allograft rejection. It can be used with chemotherapy as an "intensive" treatment aiming at the complete eradication of a malignancy--with the resulting bone marrow aplasia needing an autologous or allogeneic transplantation. In either case, a dose of some 10 Gy has to be delivered in the whole body, in one session at low dose rate or fractionated between several sessions. Such a dose is usually well tolerated--at any rate it does not carry too high a risk to contribute to induce an interstitial pneumonitis or a venous occlusive disease of the liver. The antitumoral efficacy of such limited dose is mainly important against very radiosensitive tumours--first of all leukemias and lymphomas. Yet some groups use also total body irradiation in the treatment of some solid tumours of dismal prognosis--for instance in case of advanced neuroblastomas or Ewing's sarcomas.
全身照射可产生足够的免疫抑制作用以防止同种异体移植物排斥反应。它可与化疗联合使用，作为一种“强化”治疗手段，旨在彻底根除恶性肿瘤——由此导致的骨髓再生障碍需要进行自体或异体移植。在这两种情况下，都必须在全身一次性以低剂量率给予约10 Gy的剂量，或者分几次给予。这样的剂量通常耐受性良好——无论如何，它引发间质性肺炎或肝静脉闭塞性疾病的风险都不高。这种有限剂量的抗肿瘤疗效主要对非常敏感的肿瘤很重要——首先是白血病和淋巴瘤。然而，一些研究小组也将全身照射用于治疗一些预后不佳的实体瘤——例如晚期神经母细胞瘤或尤因肉瘤的情况。
